A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

OBJECTIVE: To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. METHODS: A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD c...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Jobanputra, P, Wilson, J, Douglas, K, Burls, A
Format:	Journal article
Język:	English
Wydane:	2004

Podobne zapisy

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
od: Douglas, K, i wsp.
Wydane: (2003)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
od: T. Martijn Kuijper, i wsp.
Wydane: (2017-04-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
od: Mysler E, i wsp.
Wydane: (2021-06-01)

When the first visit to the rheumatologist is established rheumatoid arthritis
od: Taylor, P, i wsp.
Wydane: (2020)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
od: Edwards, C, i wsp.
Wydane: (2008)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
od: Michael D George, i wsp.
Wydane: (2021-04-01)

Periodontal Health as Perceived by Rheumatologists and Rheumatoid Arthritis Patients
od: Natasha Proud, i wsp.
Wydane: (2023-04-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
od: Maria Sergeevna Voronina, i wsp.
Wydane: (2012-10-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
od: Kai Wei, i wsp.
Wydane: (2022-03-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
od: Basant Kumar Maheshwari
Wydane: (2018-01-01)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
od: Jobanputra, P, i wsp.
Wydane: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
od: Jobanputra, P, i wsp.
Wydane: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
od: P. Jobanputra, i wsp.
Wydane: (2002-01-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
od: Juthamas Prawjaeng, i wsp.
Wydane: (2023-05-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
od: Barton, P, i wsp.
Wydane: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
od: Barton, P, i wsp.
Wydane: (2004)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
od: Hamre HJ, i wsp.
Wydane: (2018-03-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
od: P Barton, i wsp.
Wydane: (2004-03-01)

Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist
od: Ch. Baimukhamedov
Wydane: (2020-09-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
od: Barton, P, i wsp.
Wydane: (2004)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
od: Laurette van Boheemen, i wsp.
Wydane: (2020-09-01)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
od: Clark, W, i wsp.
Wydane: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
od: Clark, W, i wsp.
Wydane: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
od: Clark, W, i wsp.
Wydane: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
od: W Clark, i wsp.
Wydane: (2004-09-01)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
od: Edwards, C, i wsp.
Wydane: (2005)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
od: James Cheng-Chung Wei, i wsp.
Wydane: (2023-07-01)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
od: Emiliano Marasco, i wsp.
Wydane: (2023-09-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
od: Basiru Ahmad Zago, i wsp.
Wydane: (2020-12-01)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
od: Tillett, W, i wsp.
Wydane: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
od: Hazan Karadeniz, i wsp.
Wydane: (2022-04-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
od: Soo-Kyung Cho, i wsp.
Wydane: (2017-12-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
od: Esteban A. Gomez, i wsp.
Wydane: (2020-10-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
od: Seogsong Jeong, i wsp.
Wydane: (2022-07-01)

Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists
od: Adriana Maria Kakehasi, i wsp.
Wydane: (2024-08-01)

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
od: Bolge SC, i wsp.
Wydane: (2016-06-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
od: Ruiz Garcia, V, i wsp.
Wydane: (2014)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
od: Ruiz Garcia, V, i wsp.
Wydane: (2011)

To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
od: Delphine Bertrand, i wsp.
Wydane: (2024-02-01)

The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”
od: E. L. Nasonov, i wsp.
Wydane: (2023-08-01)